« Back
Home /
Eribulin (mesylate)

Eribulin (mesylate)

Manufacturer	MedChem Express
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Amount	1 mg
Item no.	HY-13442A-1mg
Targets	Microtubule/Tubulin; Apoptosis
CASRN	441045-17-6
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
StorageTemperature	-80°C, protect from light, stored under nitrogen
Shipping	Dry Ice
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	826.00
Clinical_Information	Launched
Manufacturers Research_Area	Cancer
Solubility	DMSO : ≥ 100 mg/mL\|Ethanol : ≥ 100 mg/mL
Manufacturers Target	Apoptosis; Microtubule/Tubulin
Pathway	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13442A-1mg-safety-datasheet.pdf